Skip to main content
OpenTrials
Completed

NCT Number: NCT04587479

A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors

This is a Phase 1, first-in-human, open-label study of JAB-8263 to determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D) and assess the DLT. 30 subjects with advanced solid tumor will be enrolled.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Solid Tumors, Adult

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

SCRI HeatlthONE, Denver, Colorado, United States

Loading trial locations.

About this study

JAB-8263 is a small-molecule inhibitor of the highly conserved bromodomain pockets of the bromodomain and extraterminal (BET) proteins.

The objectives of this study are:

To determine the maximum-tolerated dose (MTD) and assess the dose-limiting toxicity (DLT) of JAB-8263 as a single agent to adult subjects with advanced solid tumors To assess the safety and tolerability of JAB-8263 To characterize the pharmacokinetic (PK) parameters and pharmacodynamics (PDc) To evaluate preliminary antitumor activity of JAB-8263

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects must meet all the following criteria in order to be included in the research study:

  • Subject must be ≥18 years-of-age at the time of signature of the informed consent form (ICF).
  • Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
  • Subjects with histologically or cytologically confirmed advanced solid tumors which have progressed despite standard therapy(ies), or are intolerant to standard therapy(ies), or have a tumor for which no standard therapy(ies) exists.
  • Subjects with life expectancy ≥3 months.
  • Patients must have at least one measurable lesion as defined by RECIST v1.1.
  • Patients who have sufficient baseline organ function.

Exclusion criteria

  • History (≤3 years) of cancer that is histologically distinct from the cancer under study.
  • Known serious allergy to investigational drug or excipients
  • Active brain or spinal metastases
  • History of pericarditis or Grade ≥2 pericardial effusion
  • History of interstitial lung disease.
  • History of Grade ≥2 active infections within 2 weeks
  • Known human immunodeficiency virus (HIV) infection
  • Seropositive for hepatitis B virus (HBV)
  • Seropositive for hepatitis C virus (HCV), or HCV-RNA viral levels are not detectable.
  • Any severe and/or uncontrolled medical conditions
  • History of myocardial infarction, unstable angina pectoris, coronary artery bypass graft, or cerebrovascular accident
  • Impaired cardiac function or clinically significant cardiac diseases
  • QTcF >470 msec at screening
  • History of medically significant thromboembolic events or bleeding diathesis
  • Unresolved Grade >1 toxicity
  • History of malignant biliary obstruction
  • Pregnant or breast-feeding

Treatment and study plan

JAB-8263

Drug

Variable dose, orally Q2D with 28 days each cycle

Primary outcomes

  1. Number of participants with dose limiting toxicities

    Time frame: Approximately 2.5 years

    Incidence of dose limiting toxicities (DLTs) in the dose escalation phase. A DLT is defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first treatment cycle with JAB-8263

  2. Find Recommended Phase 2 Dose (RP2D) of JAB-8263

    Time frame: Approximately 2.5 years

    Measurements of MTD (i.e. the highest dose of JAB-8263 associated with the occurrence of Dose Limiting Toxicities (DLTs) in <33% of patients) or the RP2D (i.e. the highest tested dose that is declared safe and tolerable by the Investigators and Sponsor)

Secondary outcomes

  1. Number of participants with adverse events

    Time frame: Approximately 2.5 years

    All patients participating in this study will be assessed for incidence and severity of adverse events (AEs) and serious AEs, including changes in laboratory values, vital signs, electrocardiograms, cardiac imaging and ophthalmological assessments

  2. Area under the curve

    Time frame: Approximately 2.5 years

    Area under the plasma concentration time curve of JAB-8263

  3. Cmax

    Time frame: Approximately 2.5 years

    Highest observed plasma concentration of JAB-8263

  4. Tmax

    Time frame: Approximately 2.5 years

    Time of highest observed plasma concentration of JAB-8263

  5. T1/2

    Time frame: Approximately 2.5 years

    Half life of JAB-8263

  6. Objective response rate ( ORR )

    Time frame: Approximately 2.5 years

    ORR is defined as the proportion of participants with complete response or partial response (CR+PR)

  7. Duration of response ( DOR )

    Time frame: Approximately 2.5 years

    DOR is defined as the time from the participant's initial objective response (CR or PR) to study drug therapy, to disease progression or death due to any cause, whichever occurs first.

Sponsors and collaborators

Lead sponsor

Jacobio Pharmaceuticals Co., Ltd.

Industry

Registry information

Official study title

A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-8263 in Adult Subjects With Advanced Solid Tumors

Important dates

Study start
2020
Primary completion
2024
Study completion
2024
First posted
Oct 14, 2020
Registry last updated
Jan 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.